

Local Clinical Trials Update - Pediatric Oncology

Wade Kyono, MD

Principal Investigator, Children's Oncology Group
Kapi'olani Medical Center for Women & Children



The world's childhood cancer experts



Disclosures

- I have no actual or potential conflict of interest in relation to this program/presentation

KMCWC Pediatric/AYA Hematology/Oncology Team



Randal Wada, MD




Wade Kyono, MD



Darryl Glaser, MD



Desiree Medeiros, MD




Jasmin Jensen, MD



Kelley Hutchins, DO



Stephanie Si Lim, MD



Kelley Chinen, MD



Erika Pearson, NP



Lori Kaneshige, RN



Kristi Itagaki, PharmD




Mary Mullis, MSW



Megan Yee, CCLS

Childhood Cancer in Hawai'i 2000-2021


Hawaii population estimates by race



Source: U.S. Census Bureau
American Community Survey 1-Year Estimates for 2008 through 2018

Chart: Honolulu Civil Beat

Pediatric/AYA cancers by race



Masca, A. and Kyono, W. (2022). Epidemiology, Survival, and Clinical Trial Enrollment of Pediatric Malignancies at Kapiolani Medical Center for Women and Children from 2000-2001. Manuscript in preparation.

KMCWC Pediatric/AYA Cancer - Gender and Mixed Race 2000-2021

Total 881 patients


Male
514
(58.3%)

Female
367
(41.7%)

48%
Mixed Race

- Age range at dx: 0-34 years old
- Median age at dx: 8 years old

Pediatric/AYA Cancer Type 2000-2021




Masca, A. and Kyono, W. (2022). Epidemiology, Survival, and Clinical Trial Enrollment of Pediatric Malignancies at Kapiolani Medical Center for Women and Children from 2000-2001. Manuscript in preparation.

Pediatric/AYA Race and Cancer Type

Table 1. Odds Ratio (ORs), Mixed race adjusted

	OR (compared to Whites)	95% CI
Lymphomas		
Native Hawaiian/Part Native Hawaiian	0.826	[0.419, 1.63]
Filipino	0.769	[0.391, 1.51]
Japanese	0.351	[0.126, 0.980]
Micronesian	0.339	[0.059, 1.04]
Bone Cancer		
Native Hawaiian/Part Native Hawaiian	1.64	[0.660, 4.10]
Filipino	1.75	[0.725, 4.24]
Japanese	1.42	[0.492, 4.11]
Micronesian	1.43	[0.473, 4.33]
Other Pacific Islander	4.39	[1.01, 19.1]

Survival based on sex




701
(79.6%)
Alive

180
(20.4%)
Deceased


Masca, A. and Kyono, W. (2022). Epidemiology, Survival, and Clinical Trial Enrollment of Pediatric Malignancies at Kapiolani Medical Center for Women and Children from 2000-2001. Manuscript in preparation.

Survival based on race



Masca, A. and Kyono, W. (2022). Epidemiology, Survival, and Clinical Trial Enrollment of Pediatric Malignancies at Kapiolani Medical Center for Women and Children from 2000-2001. Manuscript in preparation.

Survival based on cancer type




Masca, A. and Kyono, W. (2022). Epidemiology, Survival, and Clinical Trial Enrollment of Pediatric Malignancies at Kapiolani Medical Center for Women and Children from 2000-2001. Manuscript in preparation.


Pediatric/AYA Oncology Clinical Trial Enrollment 2000-2021

Percentage of pediatric malignancies per year participating in a clinical trial from 2000-2021

443
(50.3%)
Clinical Trial
Participants




Current KMCWC Pediatric/AYA Oncology Research Studies



Calendar Year	Pediatric Oncology
2022*	113
2021	104
2020	92
2019	81

*Note: 2022 Data capture through 4/30/2022

KMCWC Pediatric/AYA Oncology Trial Enrollment



Calendar Year	Pediatric Oncology Enrollment
2022*	55
2021	33
2020	48

*Note: 2022 Data capture through 11/2/2022 includes 15 therapeutic + 40 non-therapeutic

Pediatric/AYA Clinical Trial Activities

- **Children's Oncology Group** – University of Hawaii MU NCORP – Dr. Kyono PI
- **Beat Childhood Cancer Consortium** – Dr. Wada PI
- Other
 - **CIBMTR** – Transplant Registry - Dr. Wada
 - **SPARK** – PROs and Clinical Practice Guideline - Dr. Kyono/Dr. Sung/Toronto SickKids
 - **iPAT** – Implementing the family Psychosocial Assessment Tool - Dr. Kyono/Dr. Kazak/Nemours (pending activation)
 - **PRISM** - Promoting Resilience in Early Survivorship among AYAs with Cancer – Dr. Kyono/Dr. Rosenberg/Fred Hutchinson Cancer Center (pending activation)
 - **ONC028** - Expanded Access to ONC201 for H3 K27M-mutant and/or Midline Gliomas – Dr. Hutchins

KMCWC High Accruing Trials

Protocol	Title
COG AALL1731	Blinatumomab + chemotherapy in patients with newly diagnosed standard risk or Down syndrome B-ALL and the treatment of localized B-Lly
COG AALL1732	Inotuzumab for newly diagnosed high-risk B-ALL, MPAL, and disseminated B-LLy
COG AAML1831	AML chemo + Gemtuzumab <u>vs</u> CPX-351 with GO, and Gilteritinib for FLT3+ AML
COG APEC14B1	Project: EveryChild - A registry, eligibility screening, biology and outcome study – now with the added Molecular Characterization Initiative (Childhood Cancer Data Initiaive)
COG ACCL15N1CD	Use of evidence-based supportive care CPGs in pediatric oncology
SPARK	Symptom screening linked to care pathways for children with cancer: a cluster randomized trial

Current List of Open AYA* Trials (>22yrs)

PROTOCOL	Age Eligible	Disease
AALL1731	1 to 31 yrs	B-LLy
AALL1732	1 to 25 yrs	HR B-ALL, B-Lly, MPAL
ACNS1721	3 to 25 yrs	CNS HGG
ADVL1823	0 to 30 yrs	TRK fusion solid tumor/leukemia
AGCT1531	0 to 49 yrs	GCT
AHEP1531	0 to 30 yrs	HCC and Hepatoblastoma
AREN1721	1 to 125 yrs	tRCC
ARST1431	0 to 40 yrs	Rhabdomyosarcoma
S1826	12 to 125 yrs	cHL

*Majority of COG trials open to age 22 yrs, AYA defined as 15-39 yrs of age

New COG Study Activations

Protocol	Title
ACCL2031	Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
APAL2020SC	Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
AOST2031	Open vs Thorascopic Management of Pulmonary Metastases in Patients with Osteosarcoma
ACL20N1CD	Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
ACCL21C2	Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
ACNS1821	Phase 1/2 Trial of Selinexor and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
ARST2032	Newly Diagnosed Very Low-Risk and Low-Risk Fusion negative Rhabdomyosarcoma

Highlights From KMCWC Pediatric Oncology

- **Programmatic Achievements**

- Chimeric Antigen Receptor Program Startup – Dr. Lim
- Extracorporeal Photopheresis Program Startup – Dr. Jensen
- Hematopoietic Progenitor Cell Transplant Program – Dr. Wada

- **National/International Efforts**

- Children's Oncology Group NCI Community Oncology Research Program (NCORP) Chairman – Dr. Kyono
- Beat Childhood Cancer Scientific Committee Member – Dr. Wada
- 2022 International Society of Paediatric Oncology Oceania Workshop – Dr. Kyono/Dr. Hutchins
- 2024 International Society of Paediatric Oncology Congress, Honolulu – KMCWC Host/Dr. Kyono Chair LOC

Mahalo!



The world's childhood cancer experts



**HAWAII
PACIFIC
HEALTH** | KAPI'OLANI
PALI MOMI
STRAUB
WILCOX